Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update

Heron Therapeutics, Inc. (NASDAQ:HRTX) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 28,810,000 shares, a decrease of 6.0% from the October 15th total of 30,640,000 shares. Based on an average trading volume of 1,830,000 shares, the days-to-cover ratio is currently 15.7 days.

Institutional Investors Weigh In On Heron Therapeutics

A number of hedge funds have recently bought and sold shares of HRTX. Marshall Wace LLP raised its stake in Heron Therapeutics by 256.2% during the second quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock valued at $6,164,000 after purchasing an additional 1,266,697 shares in the last quarter. Clearline Capital LP raised its stake in Heron Therapeutics by 48.9% during the third quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock valued at $4,431,000 after purchasing an additional 731,246 shares in the last quarter. AQR Capital Management LLC raised its stake in Heron Therapeutics by 1,460.9% during the second quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock valued at $2,125,000 after purchasing an additional 568,238 shares in the last quarter. Congress Park Capital LLC raised its stake in Heron Therapeutics by 25.3% during the third quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock valued at $3,936,000 after purchasing an additional 399,577 shares in the last quarter. Finally, Squarepoint Ops LLC raised its stake in Heron Therapeutics by 369.0% during the second quarter. Squarepoint Ops LLC now owns 363,700 shares of the biotechnology company’s stock valued at $1,273,000 after purchasing an additional 286,160 shares in the last quarter. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Stock Performance

Shares of NASDAQ:HRTX opened at $1.19 on Wednesday. The firm has a fifty day moving average price of $1.80 and a 200 day moving average price of $2.49. Heron Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $3.93. The firm has a market cap of $181.00 million, a price-to-earnings ratio of -6.61 and a beta of 1.81.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). The business had revenue of $32.81 million for the quarter, compared to analysts’ expectations of $36.40 million. During the same period in the previous year, the company earned ($0.17) EPS. As a group, research analysts predict that Heron Therapeutics will post -0.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HRTX has been the subject of a number of research reports. Needham & Company LLC dropped their target price on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. StockNews.com upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, November 13th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.